Biocryst Pharmaceuticals reported $14.12M in Interest Expense on Debt for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Adamas Pharmaceuticals ADMS:US 3.5M 28K
Alexion Pharmaceuticals ALXN:US $ 27.1M 0.6M
Alnylam Pharmaceuticals ALNY:US $ 40.27M 6.86M
Biocryst Pharmaceuticals BCRX:US $ 14.12M 0.62M
Chemocentryx CCXI:US $ 0.67M 0.03M
Gilead Sciences GILD:US $ 250M 6M
Karyopharm Therapeutics KPTI:US $ 8.01M 3.01M
Neurocrine Biosciences NBIX:US $ 6.6M 0.4M
Novavax NVAX:US $ 5.18M 0.79M
Ptc Therapeutics PTCT:US $ 21.8M 0.76M
Regeneron Pharmaceuticals REGN:US $ 14.2M 0.2M
Sarepta Therapeutics SRPT:US $ 16M 0.16M
Vertex Pharmaceuticals VRTX:US $ 15.26M 0.22M
YTE INCY:US $ 0.44M 0.08M
Zogenix ZGNX:US $ 3.85M 0.06M